trending Market Intelligence /marketintelligence/en/news-insights/trending/k_nqeyw7r9k916fpwvg2ra2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Teva taps senior VP to lead generic-drug unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva taps senior VP to lead generic-drug unit

Teva Pharmaceutical Industries Ltd. has appointed John Nason to lead its Teva Active Pharmaceutical Ingredients unit, the leading global provider of active pharmaceutical ingredients.

As president, Nason will oversee the Teva unit that manufactures generic drugs and a portfolio of specialty medicines. He will be based in Teva's global headquarters in Petach Tikva, Israel.

Nason has worked for Teva since 2015 as senior vice president of European technical operations. According to the company's Sept. 5 statement, he worked at Bristol-Myers Squibb Co. for 12 years prior to his time with Teva.